Status:
TERMINATED
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
Lead Sponsor:
Loma Linda University
Conditions:
Non-small Cell Lung Cancer
Squamous Cell Carcinoma of the Head and Neck
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The standard of care for head and neck and lung cancer includes chemotherapy, radiation and surgery. For patients with cancer of head and neck or lung that recurs after surgery and/or radiation, or ha...
Detailed Description
Azacitidine will be given with standard dose of cisplatin. At the beginning of the study, three patients will be treated with low dose of azacitidine. If that dose does not cause bad side effects, the...
Eligibility Criteria
Inclusion
- Patients must have histologically proven squamous cell carcinoma of head and neck or non-small cell lung cancer that is either metastatic or has persisted or recurred following definitive surgery and/or radiation therapy, and is not amenable to salvage surgical resection.
- Patients may have received previous chemotherapy and/or biological treatment such as cetuximab, bevacizumab or erlotinib) for the recurrent or metastatic disease. Prior treatment must have been completed at least 28 days (42 days for nitrosoureas or mitomycin C) prior to entering the study and all toxicities must have been resolved. Patients who have received prior treatment with EGFR inhibitor alone such as cetuximab or erlotinib are allowed to enter the study at least 14 days after receiving the last dose of the prior treatment.
- Prior radiation must have been completed at least 28 days before entry into the study and all toxicities must have been resolved (no more than 3000 cGy to fields including substantial marrow).
- Surgery must have been completed at least 28 days 28 days before entry into the study and all complications/adverse events must have been resolved.
- Age \>18 years.
- ECOG performance status \<2 (Karnofsky \>60%).
- Life expectancy of greater than 3 months.
- Patients must have normal organ and marrow function
- Patients must not be planning to receive any other concurrent therapy (i.e. radiation, chemotherapy, immunotherapy, biological therapy or gene therapy) while they are on this study.
- Patients must be able to understand and sign a written informed consent document approved for this trial.
- Women of childbearing potential must have a negative serum pregnancy test prior to azacitidine treatment.
Exclusion
- Patients with symptomatic brain metastases are excluded from this clinical trial. Patients with asymptomatic brain metastases are allowed. The patient must be stable for 2 weeks after radiotherapy; if the patient is on corticosteroids, the dose of cortico steroids must have been stable for 2 weeks prior to first dose of study treatment, or be in the process of being tapered.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to azacitidine, cisplatin and mannitol or other agents used in study.
- Pregnant or nursing women may not participate in this trial because of the increased risk of fetal harm including fetal death from the chemotherapeutic agents. Women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients known to be HIV-positive are not eligible because of the potential to confound this study's endpoints.
- No prior malignancy is allowed except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer or other cancer for which the patient has been disease-free for five years.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00901537
Start Date
February 1 2009
End Date
October 1 2011
Last Update
April 17 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Loma Linda University Cancer Center
Loma Linda, California, United States, 92354